CSL Plasma chooses OrSense's NBM200 Hb testing device for screening Hb levels in plasma donors

OrSense Ltd., developer of solutions for non-invasive measurements of hemoglobin, today announced that CSL Plasma, Germany, has completed the transition to OrSense's NBM200 Hb testing device for screening of Hb levels in plasma donors.

CSL Plasma is one of the world's largest plasma collection organizations, operating collection centers across the United States and Germany.

Deployment of the NBM200 systems in all collection centers in Germany started earlier this summer after a thorough evaluation and has now been completed.

Historically, Hb measurement required collection of blood samples, rendering the testing procedures invasive, painful, time consuming and labor intensive. OrSense's NBM200 offers a non-invasive solution for accurate Hb measurements that eliminates pain, reduces infection risk and enables swift Hb level analysis. The NBM200 solution is also environmentally friendly, as it requires no consumables such as lancets, gloves etc., and no need for hazardous waste handling.

Commented Yoav Reisman, CEO of Orsense: "We are happy and proud of CSL's selection of the NBM200. CSL was looking to improve donors' experience and streamline operations and the NBM200 provided both. The NBM200 is the most common Non invasive Hb screening product in blood banks today, in use by dozens of operators around the world and this entry into the world of international plasma collection organizations is a natural expansion".

SOURCE OrSense

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
The connection between severe COVID-19 and white blood cell counts